This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Wasielewski, R. Articles by Georgii, A. Search for Related Content PubMed PubMed Citation Articles by von Wasielewski, R. Articles by Georgii, A.

American Journal of Pathology, Vol 151, 1123-1130, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Classical Hodgkin's disease. Clinical impact of the immunophenotype

R von Wasielewski, M Mengel, R Fischer, ML Hansmann, K Hubner, J Franklin, H Tesch, U Paulus, M Werner, V Diehl and A Georgii
Pathologisches Institut, Medizinischen Hochschule Hannover, Germany.

Antibodies against CD15, -30, and -20 are often used to support morphological diagnosis of Hodgkin's Disease (HD). The classical HD, i.e., the non-lymphocyte-predominance types, are CD15+, CD30+, and CD20- in general. However, the results for CD15 are less clear-cut in many studies, showing up to 40% of classical HD that lack positivity for this maker. Little is currently known about the relevance of antigen expression in relation to clinical outcome in HD. Therefore, the three markers were analyzed in 1751 cases from the German Hodgkin Study Group, using micro-wave epitope retrieval to optimize staining sensitivity. Eighty-three percent of the cases showed a classical immunophenotype (CD15+, CD30+, CD20-), twelve percent lacked CD15 positivity (CD15-, CD30+, CD20-), and five percent showed other combinations. For 1286 cases, clinical follow-up was available, which revealed significant differences for freedom from treatment failure (P = 0.0022) and overall survival (P = 0.0001) between cases with classical immunophenotype and CD15 negativity (CD30+, CD20-). Multivariate Cox regression using the three markers, age, sex, histology, stage, B-symptoms (fever, sweats, weight loss > 10% of body weight), hemoglobin, and erythrocyte sedimentation rate as factors showed that lack of CD15 expression in classical HD is an independent negative prognostic factor for relapses (P = 0.022) and survival (P = 0.0035). In conclusion, immunohistochemistry is able to identify classical HD cases with unfavorable clinical outcome.

This article has been cited by other articles:

				W. Pellegrini, G. Bresciani, A. De Zorzi, D. Marocolo, M. Ungari, and F. Facchetti MMA monoclonal antibody is a superior anti-CD15 reagent for the diagnosis of classical Hodgkin's lymphoma Haematologica, May 1, 2007; 92(5): 708 - 709. [Abstract] [Full Text] [PDF]

				N. Asano, A. Oshiro, K. Matsuo, Y. Kagami, F. Ishida, R. Suzuki, T. Kinoshita, Y. Shimoyama, J.-I. Tamaru, T. Yoshino, et al. Prognostic Significance of T-Cell or Cytotoxic Molecules Phenotype in Classical Hodgkin's Lymphoma: A Clinicopathologic Study J. Clin. Oncol., October 1, 2006; 24(28): 4626 - 4633. [Abstract] [Full Text] [PDF]

				S. von Wasielewski, J. Franklin, R. Fischer, K. Hubner, M. L. Hansmann, V. Diehl, A. Georgii, and R. von Wasielewski Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages Blood, May 15, 2003; 101(10): 4063 - 4069. [Abstract] [Full Text] [PDF]

				A. Tzankov, J. Krugmann, F. Fend, M. Fischhofer, R. Greil, and S. Dirnhofer Prognostic Significance of CD20 Expression in Classical Hodgkin Lymphoma: A Clinicopathological Study of 119 Cases Clin. Cancer Res., April 1, 2003; 9(4): 1381 - 1386. [Abstract] [Full Text] [PDF]

				G. Z. Rassidakis, L. J. Medeiros, S. Viviani, V. Bonfante, G.-P. Nadali, T. P. Vassilakopoulos, O. Mesina, M. Herling, M. K. Angelopoulou, R. Giardini, et al. CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome J. Clin. Oncol., March 1, 2002; 20(5): 1278 - 1287. [Abstract] [Full Text] [PDF]

				S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al. Hodgkin's lymphoma: the pathologist's viewpoint J. Clin. Pathol., March 1, 2002; 55(3): 162 - 176. [Abstract] [Full Text] [PDF]

				R. von Wasielewski, S. Seth, J. Franklin, R. Fischer, K. Hubner, M. L. Hansmann, V. Diehl, and A. Georgii Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors Blood, February 15, 2000; 95(4): 1207 - 1213. [Abstract] [Full Text] [PDF]

				H.-D. Foss, R. Reusch, G. Demel, G. Lenz, I. Anagnostopoulos, M. Hummel, and H. Stein Frequent Expression of the B-Cell-Specific Activator Protein in Reed-Sternberg Cells of Classical Hodgkin's Disease Provides Further Evidence for Its B-Cell Origin Blood, November 1, 1999; 94(9): 3108 - 3113. [Abstract] [Full Text] [PDF]

				P. Brice Prognostic Factors in Advanced Hodgkin's Disease -- Can They Guide Therapeutic Decisions? N. Engl. J. Med., November 19, 1998; 339(21): 1547 - 1549. [Full Text]